Healthcare-Associated Infections Group, Leeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds.
Department of Microbiology, Leeds Teaching Hospital NHS Trust, Old Medical School, Leeds General Infirmary, Leeds, UK.
Curr Opin Gastroenterol. 2021 Jan;37(1):9-14. doi: 10.1097/MOG.0000000000000695.
Trehalose metabolism appears to play a role in the pathogenicity of some microbes. It has been claimed that trehalose consumption may be a risk factor for Clostridioides difficile infection (CDI), but the evidence for a causal link is contentious.
Epidemic ribotypes of C. difficile harbour mutations or have acquired extra genes that mean these strains can utilize lower concentrations of bioavailable trehalose, providing a competitive metabolic advantage in some CDI animal models. By contrast, evidence has emerged to show that trehalose-induced microbiota changes can help protect/reduce CDI in other models. In addition, C. difficile trehalose metabolic variants are widespread among epidemic and nonepidemic ribotypes alike, and the occurrence of these trehalose variants was not associated with increase disease severity or mortality.
Currently, there is no proven causal association between the incidence or severity of human CDI and the presence of trehalose metabolism variants. Furthermore, microbial metabolism reduces trehalose bioavailability, potentially removing this competitive advantage for C. difficile trehalose metabolism variants. Taken together, trehalose consumed as part of a normal diet has no increased risk of CDI.
海藻糖代谢似乎在一些微生物的致病性中起作用。有人声称,海藻糖的消耗可能是艰难梭菌感染(CDI)的一个危险因素,但因果关系的证据存在争议。
艰难梭菌的流行株系携带有突变或获得了额外的基因,这意味着这些菌株可以利用更低浓度的生物可利用海藻糖,在某些 CDI 动物模型中提供竞争代谢优势。相比之下,有证据表明,海藻糖诱导的微生物群变化可以帮助保护/减少其他模型中的 CDI。此外,艰难梭菌海藻糖代谢变体在流行和非流行株系中都广泛存在,这些海藻糖变体的出现与疾病严重程度或死亡率的增加无关。
目前,人类 CDI 的发生率或严重程度与海藻糖代谢变体的存在之间没有确凿的因果关系。此外,微生物代谢会降低海藻糖的生物利用度,可能会消除艰难梭菌海藻糖代谢变体的这种竞争优势。综上所述,作为正常饮食的一部分摄入的海藻糖不会增加 CDI 的风险。